Brief: Xspray Pharma's XS003 Study Shows Matching Bioavailability To Tasigna At More Than A 50% Lower Dose

Xspray Pharma publ AB

09/07/2024 19:33

July 9 (Reuters) - XSpray Pharma AB  XSPRAY.ST :
    * XSPRAY PHARMA AB: XS003 STUDY SHOWS MATCHING
BIOAVAILABILITY TO
TASIGNA AT MORE THAN A 50% LOWER DOSE
    * XSPRAY PHARMA AB: TO SUBMIT APPROVAL APPLICATION FOR XS003
TO
FDA IN FIRST HALF OF 2025

Source text for Eikon:  ID:nBw8wFs7Ga 
Further company coverage:  XSPRAY.ST 

 ((Reuters.Briefs@thomsonreuters.com;))